Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05962424 · ClinicalTrials.gov registry record · Phase 1
HNC: Human Neural Circuits Electrophysiology During Cognition
A Phase 1 study of Psychiatric Disorder, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05962424: Recruiting Phase 1 study of Psychiatric Disorder, sponsored by Stanford University.
NCT05962424 is a Phase 1 study of Psychiatric Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 120 participants, roughly in line with the 129-participant average among 9 other Psychiatric Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05962424, a Phase 1 study of Psychiatric Disorder, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Primary Outcome
The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms.
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-10-05 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 1 |
What NCT05962424 shows while recruiting
NCT05962424 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 129-participant average among 9 other Psychiatric Disorder trials with a reported enrollment target.
The record links to 1 condition, with Psychiatric Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ketamine Hydrochloride is the first listed.
NCT05962424 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05962424 about?
NCT05962424 is a clinical study titled "HNC: Human Neural Circuits Electrophysiology During Cognition". The purpose of this study is to understand how ketamine brings about dissociative symptoms.
What is the current status of trial NCT05962424?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-10-05. Estimated completion is 2030-09-01.
What conditions does trial NCT05962424 study?
This clinical trial studies the following conditions: Psychiatric Disorder.
What interventions are being tested in trial NCT05962424?
The interventions under investigation include: Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05962424?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05962424 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychiatric Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05962424's enrollment target sits among peer trials
120 4th of 9 higher than 6 of 9 other Psychiatric Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psychiatric Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting
RECRUITING · NA
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers
RECRUITING · NA
-
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
RECRUITING · NA
-
Neural Correlates of Psychiatric Disorders
RECRUITING
-
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI